Interview with the CEO of Moexa Pharmaceuticals, Anthony Desir

Moexa's novel patented therapeutics targets tumor related SMAD3 cells by way of the TGF-β pathway and was developed to focus on immuno-oncology and fibrosis.  Pre-IND tests demonstrate prophylactic anti cancer properties, and effective fibrosis therapeutics even in cases of SARS COVID infections.  Their related therapeutics have the added benefit of boosting NK Cell production while simultaneously promoting tumor immune tolerance.